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AIM OF THE STUDY: 
 Aim of this retrospective study is to evaluate the role of loco regional 
treatment such as local radiotherapy and surgery in the management of patient with  
metastatic breast cancer. 
MATERIALS AND METHODS: 
 One hundred and Ninety five patients with metastatic breast cancer between 
the years 2003 to 2008 were taken for this retrospective study. Among these, 
seventy five patients did not receive locoregional treatment, and the remaining one 
hundred and twenty patients received locoregional treatment to the primary. 
Locoregional treatment included radiotherapy and surgery.  
RESULTS:  
Patients survival was analyzed at the end of 1 year, 3 years, 5 years, and at 
the end of 10 years. It was found that, in patients receiving concurrent 
chemoradiation, survival at the end of 1, 3, 5 and 10 years were 89%, 58%, 46% 
and 42% respectively. Similarly, in patients receiving concurrent chemoradiation 
followed by surgery, survival was 97%, 80%, 71% and 70% respectively. Further, 
survival for chemotherapy was 60%, 5%, 2% and 0% respectively. Again, for the 
arm including only radiotherapy, survival was around 67%, 33%, 33% and 33% 
respectively. Those patients who receive only hormonal therapy had 50%, 13%, 
13% and 13% overall survival at the end of 1, 3,5 and 10 years.  
CONCLUSION: 
 The data reported in this retrospective study confirmed that chemo-radiation 
improved overall survival and symptomatic local control, demonstrated in loco-
regionally treated patients with metastatic breast cancer. 
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INTRODUCTION 
 
Evolution of breast cancer  
 
 As carcinoma of breast has no clear cause hence gained much 
attention throughout the ages all over the world.  The story of breast 
cancer is complex as there is no happy ending unlike other diseases. The 
development and milestones of breast cancer started from the ancient 
civilization of the Chinese, Egyptian, Babylonian, Greek, Greeco-
Roman, middle ages Christian, Jewish, Arabic. 
 
The Chinese form of medicine describes five forms of therapy for 
tumors. 
 
1. Spiritual care  
2. Pharmacology 
3. Diet 
4. Acupuncture 
5. Treatment of specific diseases 
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 Egyptian form of medicine was described by IMHOTEP who used 
cautery for cancer. Edwin Smith during his period obtained information 
from Papyrous roll described that breast cancer that are cold on touch 
has no treatment.  
 
 During Greek period, Hippocrates described diseases in three 
groups. 
 
Curable when medicine  
1. Curable by knife  
2. Curable by fire 
 
Hippocrates also described that breast cancer was the cessation of 
menstruation.  
 
 Greeco-Roman period – Aurelius Celsus described breast cancer 
as a fixed irregular swelling with dilated veins and ulcers and divided 
into four staged  
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1. Early cancer 
2. Cancer without ulcer 
3. Cancer with ulceration  
4. Cancer with cauliflower like growth, and advised no treatment 
for last three stages.  
 
 The first physician who operated breast cancer in the first century 
was LEONIDES. His method of surgery was by using incision from the 
uninvolved part of the breast and applied cautery to stop bleeding, the 
same method was repeated until the whole breast is removed and the 
underlying tissue was covered with eschar. Galen described breast 
cancer was due to black bile and said breast cancer looks like a crabs leg 
and suggested patient to be purged and bleed and to let out the tumor in 
early stages.  
 
 From Middle Ages – downfall of Romans – beginning of 
Renaissance - Christian 
 
 During this period the patron of breast disease was Saint Agatha in 
the third century whose breast was cut off using sheets 
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 Arabic Rhazes advised excision of breast cancer only if it was 
completely operable. Hay ben Abbas advised compete excision of the 
disease and allowed bleeding to evacuate the bad disease.  
 
 Renaissance – from medieval to modern Era 
  
Andreas Vesalius recommended mastectomy for breast cancer and 
used sutures instead of cautery. Ambrose Pare described lymph node 
metastases of breast cancer. Serventus described the method of removal 
of pectoralis muscle with axillary glands. Wilhelm Fabry, father of 
German surgery compressed and fixed the base of breast and used knife 
to amputate the breast. Johan Schultles, German surgeon, inventor of 
surgical instruments .18
th
 Century 
 
 Henri Le Dran of France described carcinoma of breast as a 
localized disease in early stages and lymph nodal spread as bas disease 
with bad prognosis. Jean Petit, friend of Le dran advised surgery of 
breast cancer involves removal of breast, pectoral muscles and axillary 
nodes. German surgeons, Lorez and Heister advised Guillotine machine 
for breast tumor.  
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Heister described the relationship between surgeon and patient and 
said that surgeons should be stead fast and not to be disconnected by the 
cries of the patient. 
 
 19
th
 Century- period of invention of aneasthesia and antisepsis 
hence breast cancer surgery improved. 
European surgery – 
  
 Nooth  an  English surgeon sprayed carbolic acid over the breast 
instead of cautery. Syme described the need for axillary lymph node 
dissection in breast cancer patients. Charles Moore believed in extensive 
surgery for breast cancer and said that tumor should not be cut as it may 
disperse the tumor and allow recurrence of the disease. He also advised 
the entire removal of breast with skin and not to remove pectoralis 
muscle. Richard Van Volkman advised extensive surgery even for small 
tumors. Theodor Billorth also advised the same. Ernst Kuster advised 
removal of axillary fat with axillary nodes. Lothar Heidenhain advised 
removal of superficial pectoralis major muscle. Everard Home showed 
appearance of cancer cells under microscope. Henrich Van 
WaldeyerHantz described carcinoma arising from epithelial tissue and 
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sarcoma from mesodermal tissue. Victor Cornil described malignant 
transformation of acinar epithelium of breast. David Van Hansemann 
described diffentiation of cancer cells (ANAPLASIA)  
American Surgery 
  
 Joseph Pancoast described the pre-anesthetic era of mastectomy 
with axillary lymphatic drainage. Samuel.D.Gross described breast 
conservation surgery. William Halsted advised removal of breast cancer 
with pectoralis muscle. William Meyer modification of Halsted’s 
procedure advocated removal of pectoralis minor muscle along with 
pectoralis major. Cullen and William Welch was the first to do the 
frozen session of the breast in the diagnosis of breast cancer.  
 
 20
th
 century it became evident that cure can be achieved by 
surgery. Halsted and Meyer surgery didn’t include supra clavicular and 
internal mammary nodes and its removal did not show any improvement 
in survival. William Handley showed the involvement of internal 
mammary node when axillary node was involved in breast cancer 
patients. Jerome and Owen Wangsteen advised supra radicle 
Mastectomy which involved dissection of mediastinum and neck. 
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Cushman Haagensen classified breast cancer according to size and nodal 
status . He was the first person to advise breast self-examination. In 1948 
the first concept of modified radical mastectomy was done by Patey and 
Dyson. Donald Morton and Giuliano developed sentinel node biopsy 
technique. In 1937 London surgeon, Geoffrey Keynes described minimal 
surgery for breast cancer and advised radiotherapy which had equally 
good result .  In 1948 simple Mastectomy followed by radiotherapy was 
introduced by R. McWhirter. 
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Radiotherapy 
 
 Emile Grubbe medical graduate studying 2
nd
 year from Chicago 
was the 1
st
 person to irradiate breast cancer patients, he used tin foil to 
protect the normal skin to protect the normal skin  
 
 In 1896 Hermann Gocht of Germany treated breast cancer patients 
with radiation and used flexible led to protect normal tissue  
 
In 1903 1
st
 department of radiotherapy was founded by J.Pollock 
in London George Perthes a surgeon from Germany described curative 
effect of X- rays  
 
 Post op radiotherapy was used in America and Europe before 
world war I. before world war I energy used was 150kv X-rays, after 
world war II 170-200kv X-rays was used  
 
 In 1929 S. Harrington of the mayo clinic studied 1859 breast 
cancer patients irradiated between 1910-1923. He expressed doubts 
about ancillary RT George Pfahler from Philadelphia adviced post op RT 
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for all cases of breast cancer after 2 weeks of surgery. In his review of 
102 patients there is no significant benefit in survival in stage I patients 
but showed a improved 5 year survival in stage II patients. 
  
 Radiotherapy as a single modality for breast cancer was used in in 
operable cases during the beginning of 20
th
 century until 1922. 
 
William Stone from New York showed the benefit of RT over 
surgery in inoperable breast cancer based on his experience on 10000 
patients. 
 
Geoffrey Keynes from London in 1932 used radium for 
therapeutic use irradiation and showed 5 years survival rate of 77% in 
node negative patients and 36% with node positive patients. 
 
 1930 super voltage X-rays were available .Francois Baclesse of 
Paris did local excision of breast cancer followed by RT from 1937-
1953, and said that results were equal for stage I and stage II breast 
cancer , between post op RT vs only surgery. 
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 In 1948 Robert McWhirter proposed simple mastectomy followed 
by RT He said radical mastectiomy was over kill for stage I breast 
cancer, but inadequate for stage II breast cancer. 
 
 1960 cobalt emerged 
 1970 linear accelerator emerged  
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Chemotherapy 
 
 Paul Ehrlich was the father of chemotherapy.Arsenic was used in 
ancient times for breast cancer treatment. 
 
 1898 1st alkylating agent was used. 
 World war II nitrogen mustard came into use . 
 1957 C. Heidel Berger used 5FU in breast cancer. 
 In 1958 thiotriethylenephospharamide alkylating agent. 
 1963 E.Greens Span used multi drug trials using methotrexate 
with thiotepa. 
 Gianni Bonodona was the 1st person to start CMF regimen in 
breast cancer. 
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Hormone therapy 
 
 Hormone therapy in breast cancer patients was started even before 
20
th
 century in 1889- Schinzinger of Germany proposed oophorectomy 
before mastectomy . 
 
 In 1896-1901 George Beatson advised oophorectomy for breast 
cancer patients . 
 
 In 1900 Boyd was the 1
st
 person to combine oophorectomy with 
mastectomy. 
 
 In 1953 Charles Higgnes combined oophorectomy and 
adrenalectomy . 
 
 In 1950s hypophysectomy was done  for advanced breast cancer. 
 1939 P.Ulrich used testosterone for breast cancer . 
 In 1944 Alexander Haddow used synthetic oestrogen . 
 In 1938 Edward Dodds synthesized stilbesterol. 
 I.Naphasyn also synthesized stilbesterol . 
 In 1950-1960 oestrogen and androgens was used much. 
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 In 1973 W.McGuire demonstrated oestrogen receptors in breast 
 cancer patients . 
 In 1975 K.Horowitz demonstrated progesterone receptors. 
 In 1980 tamoxifen and SERM was used 
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History of staging 
 
 Has a long history surgeons divided into two groups to decide on 
surgery either inoperable or operable, on the basis of certain observations 
staging was initiated . 
 
 Steinthall’s grouping 
 Group1 
 Group 2 
 Group3  
 In 1940 manchester classification consists of  
 stageI 
 stage II 
 stage III 
 stage IV 
 Portmann classification  
 
 In 1943 CCC(cloumbia clinical classification )evolved from 
Haagensen and Stout’s 
Stage A-D 
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 In 1954 UICC emerged started TNM classification developed by 
Pierre Denoix of France  
 
 In 1962 AJCC emerged .Carcinoma breast is the most commonly 
diagnosed cancer in women all over the world, affecting nearly 21% of 
all cancer diagnosed in females a with high ratios in North America, 
Western Europe, intermediate rates in South America and Eastern 
Europe and low rates in Asia. 10 percent of newly diagnosed breast 
cancer patients have metastatic breast cancer. After all treatments  nearly 
one third of patients  will have progressive disease .   metastatic breast 
cancer median survival for the 3 yrs. 
 
 The range is very wide  with some patients having more indolent 
disease that they can live upto 10 – 15 years, while for others with 
disseminated metastatic disease, the prognosis will  be in the range of 
months from the time of diagnosis. This will represent the disease  extent 
and distribution of metastatic disease, and  reflects the biological 
behaviuor of carcinoma of breast, while some women have disease 
which  shows  good  response  to hormonal treatments, while  others  
with   triple negative breast cancer can  show  increased  resistance to all 
systemic therapies. 
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 The aim of treatmentic breast cancer is to increase the  symptom 
free survival and increase  quality of life . at the same time the side effect  
of the treatment to be minimised. The treatment for metastatic breast 
cancer is depends on the individual patient and receptor status, general 
condition of the patient. Even with newer systemic and locoregional 
treatment mestatic breast cancer cannot be cured at present.In few 
pateints with good prognostic factor these treatment modalities increases 
the progression free survival which inturn may significantly affects the 
overall survival. Many patients with metastases may live several  years 
with modern locoregional treatment and systemic chemotherapy. 
 
Regions No.of Cases CIR ASR
World 1676633 47.9 43.3
More Developed 
Region
793684 124.1 74.1
Less Developed 
Region
882949 30.9 31.3
India 144937 23.8 25.8
Chenai (09-10) 1568 34.2 35.7
Breast Cancer Statistics
Source: Globocan 2012,IARC Publications & MMTR  Report
CIR: Crude Incidence Rate per 100000 Populations
 
TOTAL NO OF BREAST CASES IN CHENNAI IN THE YEAR OF 
2012 - 1568 
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NATURAL HISTORY AND ORIGINS 
 
 Concepts regarding the natural history of breast cancer have 
undergone great evolution over the past 100 years, with a profound 
impact on the management of these patients. The Halstedmodel was 
based on an orderly progression to the regional lymph nodes and from 
there to distant metastatic sites. Later another hypothesis was fully 
demonstrated in both laboratory and clinical studies by Fisher,who 
advanced the concept that breast cancer, as a systemic process involving 
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host–tumor interactions, would not show substantial effects on survival 
with variations in locoregional treatment.  
 
 A third hypothesis putforward by Hellmanconsiders breast cancer 
as a heterogeneous disease with aspectrum extending from a tumor that 
remains localized throughout its course to one that disseminates 
systemically, even when detected as a small lesion, suggesting that 
metastases are a function of tumor growth and progression factors. 
 
BREAST CANCER RISK FACTORS 
 
Established Risk factors,  
1. Age of the patient 
 Early Menarche, late menopause, Age at first child birth( related 
to estrogen exposure) 
 
1. Duration of Breast feeding 
 Decreasing the breast cancer risk by delaying ovulation and 
decreasing the hormone exposure 
2. Height weight and body mass index 
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3. Physical activity 
4. Alcohol consumption 
5. High dose estrogen containing oral contraceptive pills 
 And hormone replacement therapy in postmenopausal women 
6. Inonizing Radiation 
7. Family history and genetic susceptibility 
 
Possible risk factor 
1. Fat and future 
2. Dietary phytooestrogen 
 Hereditary breast cancer 
 
 5-10% of the breast cancer is due to familial risk factor. 
 The breast cancer susceptibility genes divided into three types. 
1. High penetrance 
2. Intermediate penetrance  
3. Low penetrance  
 
 Low penetrance are the most common variety BRCA1 and 
BRCA2 genes Fifty percent of the familial breast cancers are mainly due 
to BRCA1 and BRCA2 genes. 
20 
 
 This increases the relative risk of the cancer breast to 10 to 30 
times of the normal population. 
 
 The prevalence is more common in jewish population. BRCA1 
mutations characteristically has a basal – like phenotype, inactivating 
germiline mutation. The similarity between hereditary  BRCA1-related 
sporadic BLBC sporadic basal like breast cancers may also harbor an 
underlying defect in BRCA1, which has been termed “BRCAness”. 
BRCA2 – related cancers do not have an association with TNBC or the 
basal – like phenotype. Other rare breast cancer susceptibility genes 
related to the breast cancer are CHEK2,TP53,PTEN,STK11 
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DISTIBUTION 
 
 Upper outer quadrant is the most common site of carcinoma breast 
which contributes about 38% of the total incidence. The second common 
site is the central area of the breast followed by upper inner quadrant and 
then the lower inner quadrant. 
 The distribution correlates with the difference in density of breast 
tissue in various quadrants. 
 
LOCAL SPREAD 
 
 During the development and progression of the breast carcinoma, 
it starts from the ducts and then breaches the basement membrane enters 
into the surrounding breast parenchymal structure. The tumor can grow 
through the wall of blood vessels, spread into the deep lymphatics of the 
dermis, and eventually produce edema of the skin (peaud’orange), which 
usually indicates that the superficial as well as the deep lymphatics are 
involved. Skin dimpling can be caused by involvement of Cooper’s 
ligament. Ulceration and infiltration of overlying skin, which may 
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develop late in the course of the disease, are usually preceded by fixation 
and localized redness of the skin over the tumour. 
 
Axillary Spread 
 
 Majority of the breast carcinoma spread through axillary nodes 
and the percentage of the nodal involvement increases with tumour size. 
The percentage varies from between 10% and 40% depending on the size 
of the tumour. 
 
Supraclavicular Spread 
 
 Spread to supraclavicular lymph nodes usually follows 
involvement in the high axillary lymph nodes or IMNs. Clinical failure 
in the supraclavicular fossa is relatively rare in patients with early-stage 
breast cancer and is dependent on the degree of axillary involvement. 
For patients with no or minimal nodal involvement (less than three 
involved axillary nodes), supraclavicular failure is extremely rare. 
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Internal Mammary Spread 
 
 Metastases to the internal mammary nodes (IMNs) are correlated 
with tumour size, are more frequent from medial half and central lesions, 
and occur more frequently when there is axillary node involvement  
 
Systemic Spread 
 
 Of the systemic metastasis,  
 Approximately 60% are in bone, 
 10% in lungs,5% in liver,  
 5%in central nervous system  
 15 to20% in multiple sites. 
 
ANATOMY 
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 The female breasts are modified eccrine glands on the anterior 
chest wall, superiorly frim the second rib to inferiorly upto the 6
th
 rib, 
medially to the sternal edge and laterally upto the mid axillary line. The 
breast parenchyma is composed of lobules and ducts. The function of the 
lobules is to produce milk and the function of the ducts is to transport 
lactation products to the nipple The breast parenchyma is intermixed 
with connective tissue, which has a richvascular and lymphatic network. 
Mammary gland lymphatics begin in the interlobular or prelobular 
spaces, follow the ducts, and end in the sub areolar network of 
lymphatics of the skin.  
 
Lymphatic drainage of the breast  
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 The predominant lymphatic drainage of thebreast is to axillary 
lymph nodes,The level I axilla iscaudal and lateral to the muscle, level II 
is beneaththe muscle, and level III is cranial and medial to 
themuscleLymphatics can also drain directly into theinternal mammary 
lymph node chain (IMC), whichareintrathoracic structures located in 
theparasternal space. Although these nodes are notusually visualized on 
computed tomography (CT),the anatomical region of the IMC can be 
determinedby the internal mammary artery and vein, which areeasily 
visualized by CT (Fig. 56.3 ) and usually lie3 to 4 cm lateral to midline 
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PATHOLOGY 
 
 Breast carcinomas are divided in to insitu carcinoma and invasive 
carcinoma  
 
 Insitu carcinoma are divided into ductal carcinoma insitu and 
lobular carcinoma insitu. 
 
INVASIVE CARCINOMAS  
 
 The histological typing of breast cancer is made by exclusion 
INVASIVE DUCTAL CARCINOMA (NOS) is an invasive carcinoma 
that doesn’t fulfil definition of other categories.  
 
 Invasive lobular carcinoma, tubular carcinoma, mucinous 
carcinoma, cribri form carcinoma, papillary carcinoma, scirrhous 
carcinoma, comedo and medullary carcinomas are fuse specified types of 
breast carcinoma.  Histological used in the Brest cancer is proposed by 
elston and ellis it is the modification of bloom rich at son in 1957 it has 3 
factors  
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1. Tubule formation  
2. Pleomorphism 
3. Mitotic activity  
 
Each factor scored on a scale of 1-3 tubule formation  Histological 
grade  
3 – 5  - well differentiated tumours  
6 – 7  - moderately differentiated  
8 – 9  - poorly differentiated  
 
Luminal A 
 
 100% ER positive,70% ER positive, good risk , 10 years relapse 
free survival 70%, low risk on oncotype Dx and Mamma print and 
hormone responsive tamoxifene responsive ,chemo insensitive ,Ki 67% 
<14% primary tumor 62% T1 , 38% T2 , HER2 negative , 
 
Luminal B  
 
 ER positive less than 50%, PR positive bad prognosis , 10 years 
relapse free survival 53% ,tamoxifene insensitive , aromatase inhibitor 
sensitive , Ki 67% more than 14% ,younger age higher grade , 30% are 
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HER2 positive ,Intermediate to high risk on oncotype DX and Mamma 
print  
 
Basal type 
 
 Do not express ER,PR or HER2 negative 85% (triple negative) are 
basal 
 
 Express myoepithelial cell membrane CK5 , C-Kit ,EGFR, HER2 
tends to be high grade . 
 
NG-III, present with large tumours T2 and above 
chemoresponsive high relapse rate in CNS 
 
BRCA1 tend to be basal line common in African Americans  
 
Angiogenesis  
 
 Targeting angiogenesis in metastatic breast cancer Judah Folkman 
in 1970 first described the concept of angiogenesis by targeting blood 
vessel formation by preventing tumour growth and metastasis . he 
defined anti angiogenesis therapy which causes regression of tumour by 
altering tumour vasculature , normalization of surviving tumour 
vasculature , inhibition of regrowth of vessel and neovascularisation in 
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tumours, eg. antiVEGF antibody-Bevacizumab dose:10mg /kg every 
2weeks of 15mg /kg every 3weeks 
Prognostic bio marker  
 
 Indicates the proabablity of specific clinical outcome such as 
recurrence progression survival independent of treatment 
Predictive bio marker 
 Indicates the chance of response to specific therapy  
 Response indicator  
 Monitors response and assist in stop vs continue treatement 
 Pharmacokinetic bio marker  
 It measures pharmacokinetic parameters of drug exposure  
 Pharmacodynamic bio marker 
 Measures end point of drug effect on target pathway and 
 downstream biological process  
 Prognostic multigenes signatures in carcinoma breast 
 Mamma print –microarray-70genes –freshfrozen tissue  
 Rotterdam signature-microarray-76 genes-freshfrozen tissue 
 Genomic grade index-microarray-97genes-freshfrozen tissue 
 Mammostrat IHC-5genes-Formaline embedded fixed paraffin 
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 Oncotype DX –qRT-PCR-21 genes- Formaline embedded 
 fixed paraffin 
 
DIAGNOSTIC EVALUATION 
 
History 
 
 Complaints related to the breast cancer and history related to the 
risk factors to be elicited history of any lump in the breast, nipple 
discharge, skin changes, any axillary swellings to be asked.  
 
Physical examination  
 
 It includes inspection and palpation of the breasts, axilla, 
supraclavicular region,  
 
 The breast is examined by various positions including sitting with 
arms either side, sitting positions with arms above the patient’s head, 
patient’s hands pressed against her hips the following changes in the 
breast to be noted  
1. Any asymmetry of the breast  
2. Inverted nipple 
3. Skin changes 
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Palpation of breast.  
 It should be perform with the patients in supine position and also 
in sitting position  
 
Signs of breast cancer. 
 
1. Palpable mass  
2. Nipple discharge- unilateral bloody discharge  
3. Nipple changes – any retraction, infiltration, pagets . 
4. Skin changes – dimpling or skin retraction. 
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Biopsy 
 
 The following important factors to be identified in the specimen 
which is needed for further management.   
 
Hormone receptor status – ER,PR status  
 
1. HER2 neu status  
2. Histological type of cancer  
3. Histological grading  
 
Baseline investigations 
1. Complete blood count 
2. Blood biochemistry 
3. Liver function test 
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4. Renal function test 
5. X ray chest PA view 
6. Ultrasound abdomen and pelvis 
7. Ct chest 
8. Bilateral mammogram.  
 
MAMMOGRAM 
 
 Mammogram provides additional information  
 In the presence of palperable mass mammography is useful in 
detecting occult lesion in same or opposite breast, it is classified as 
screnning mammography of diagnostic mammography  
 
 Screening mammography to screen asymptomatic women 
Diagnostic mammography is a definite imaging workup to locate a 
mammographically visible lesion  
 
IMPORTANCE OF MAMMOGRAPHY IN BREAST CANCER  
 
 Reduction in breast mortality  
 Swedish country trial 30% (40-74 years) 
 Malmo trial 36% (45-49 years) 
 Gottenberg trial 45% (39-49 years) 
 Metaanalysis of 5 swedish trials 29% (40-59 years) 
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TYPE OF VIEWS 
 In screening mammography –two views, mediolateral oblique 
view and cranio caudal view 
 
 In  diagnostic mammography – mediolateral view craniocaudal 
view and exaggerated CCL –CCM 
 
MAGNIFICATION VIEWS  
 
 BI-RADS ( british imaging reporting and data system) false 
negative 75-80% due to dense breast in young women 
 
Classification  
Category 0 – assessment incomplete used in screening 
Category 1 – normal 
Category 2 – benign finding 
Category 3 – benign probably   
Category 4 –  malignancy suspected 
Category 5 –  malignant 
What is triple diagnosis?  
Physical finding  
FNAC 
Mammogram 
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WHAT IS A MASS? 
M –mobility   T – tenderness 
A –attachement  L - location 
S –shape   C - consistency  
S – size  
 
DEFINED AS A  PALPABLE ABNORMALITY DISTINCT FROM 
SURROUNDING TISSUE 
 
USG of breast 
 
 USG of breast is a useful complement to mammography for 
evaluation of dense breast when results of physical examination and 
mammography are equivocal useful in these group of patients 
 
1. Those with dense breast and localized sysmptoms of with a 
suspicious area detected in MMG 
2. Those with non palpable abnormality discovered on MMG 
3. Those with palpable masses considered intermediate on MMG 
4. To guide aspiration of non palpable cystic structure  
5. To do FNAC of small lumps 
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MRI of breast  
 
Sensitivity 97-99% 
Specificity 28-37% 
Greatest strength of MRI to detect occult metastasis in dense 
breast and recurrence after irridation 
FDG PET scan 
Sensitivity 93% 
Specificity 73% 
Accuracy 89% 
Positive predictive value 92% 
Negative predictive value 96% 
False negative 20% 
Bone scan: technetium 99, F18 – more specific recommended for 
stage II and above cancers and T size >2cm  
 
 The mammographic findings for malignancy include ill definded 
mass with spiculatlions, micro calcifications (100 to 300 um rod like, 
tubular, branching or punctuate) and architectural distortion. 
 
Magnetic Resonance Imaging 
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Indications 
 
 To assess the silicone implant integrity 
 To diagnose the malignancy in reconstructed breast 
 To rule out multifocal disease before doing Breast reconstructive 
surgery 
 To assess the response to neoadjuvant chemotherapy 
 To diagnose the occult primary. 
 
 Positron Emission tomography  The metabolism of the tumour 
cells are mainly by glycolysis not by oxidative metabolism   
 
 This difference between tumor cells and normal cells is the basis 
for the PET imaging. 
 
Uses  
 
1. To differentiatiate the recurrent breast cancer from postoperative 
scar. 
2. Have high accuracy in detecting presence or absence of lymph 
node involvement 
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3. Able to screen the whole body in a single imaging method for 
distant metastasis 
4. Pet is very much useful in the quantitative response assessment 
after neoadjuvant chemotherapy. 
 
STAGING (TNM CLASSIFICATION) AJCC 2010 
 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 mic Tumor</=1 in greates dimension  
T1a Tumor>1<5 mm in greatest 
dimension 
T1b Tumor>5<10 mm in greatest 
dimension  
T1c Tumor>10>20 mm in greatest 
dimension  
T2 >2<5cm in greatest dimension  
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T3 >5cm in greatest dimension  
T4a Extension to chest wall not including 
pectoralis muscle  
T4b Ulceration and/or ipsilateral satellite 
nodules and/or edema (including 
peau d’ orange) of the skin  
T4c Both T4 a and T4b 
T4d Inflammatory carcinoma  
Nx Regional lymph nodes cannot be 
assessed 
No No regional lymph nodes 
N1 Metastases to movable ipsilateral  
axillary lymphnodes(s) 
N2a Metastases in ipsilateral axillary 
lymph nodes fixedto one another 
(matted) or to other structures 
N2b Metastases only in clinically detected 
ipsilateral internal mammary nodes 
and in the absence of clinically 
evident axillary lymph node 
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metastases  
N3a Metastases in 
ipsilateralinfraclavicular lymph node 
(s) 
N3b Metastases in ipsilateral internal 
mammary lymph nodes (s0 and 
axillary lymph node (s) 
N3c Metastases in ipsilaternal 
supraclavicular lymph node(s) 
M0 No distant metastasis 
M1 Presence of distant metastasis  
 
 
COMPOSITE STAGING  
 
STAGE 0 Tis No Mo 
STAGE1A T1 No Mo 
STAGE1B To N1 mic Mo 
STAGE2A T1 N1 mic Mo 
STAGE2B T0 N1Mo, T1 N 1 Mo, T2 No Mo  
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STAGE3A T0N2Mo, T1 N2 M0, T2 N2 M0 
T3 N1 M0, T3 N2 M0 
STAGE3B T4 N0 Mo, T3 N1 M0 T4 N2 M0 
STAGE3C Any T N3 M0 
STAGE4 Any T Any NM1 
 
 Overall survival of breast cancer patients correlates with the stage 
of diseae at presentation.  The table depicts 5 years survival according to 
stage of the disease” 
 
Stage 5 Year Survival 
0 100% 
1 98% 
2A 88% 
2B 76% 
3A 56% 
3B/C 49% 
4 16% 
 
 
42 
 
METASTASES:  
 
 The metastatic potency of cancer cells depends upon the intrinsic 
properties of tumor and their interactions with tissue environment. The 
steps of metastases include  Proliferation of tumor cells by paracrine 
growth (tissue environment), autocrine  growth (from tumor itself)-
EGFR, c-erb /HER2neu, TGF- alpha, HRG, Neovascularisation  due to 
new vessel formation by factors released by the tumor and tumor cells 
exhibit motility there by detachment and movement from the primary 
site  
 Invasion is a process by which there is destruction of basement 
membrane, connective tissues, adhesion and motility with response to 
release of factors.Distant metastases is due to release of cancer cells in to 
blood or lymphatic stream in to the body as single cell or emboli . These 
emboli gets arrested in the draining sites like lymph nodes ,organs 
,adhere to endothelial cells and capillary beds. Extravasation also 
involves same steps of invasion 8) Growth in the deposited organ  of 
metastases depends upon the responses of paracrine and auto crine 
factors of the tumor,once metastases establishes it becomes a source for 
further metastases known as “ METASTASES OF METASTASES”. 
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 The risk of relapse in carcinoma breast patients is more during the 
first 2 yrs after diagnosis and treatment, the time of events  and survival 
of cells vary in circulation within minutes to years. 
 
 Genes associated with metastases in carcinoma breast are 
S100A4/MTA-1/ Osteopontin /bcl-2/maspin.Genes associated with 
suppressing of carcinoma breast are nm23/ KAI1 /KiSS 1/BRMS1. 
Metastases in breast cancer was described by Stephen Paget base on” 
seed and soil “hypothesis . 
Role of surgery in metastatic breast cancer  
 
 At present carcinoma of breast has replaced carcinoma of cervix in 
Indian tumor registries. Survival of these patients has increased over the 
years.  Over the years systemic therapy is the treatment of chronic and 
local therapy like Radiotherapy and Surgery. 
 
Mechanism of Metastases in breast cancer 
 
 Halsted was the first person to state the therapy of metastases. 
According to him breast cancer is a localized disease in the breast and it 
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spreads to axillary nodes and to the sanctuary site. Hence he advocated 
extensive loco-regional treatment. 
 
 Bernard Fischer later defined that breast cancer was a systemic 
disease, which has a capacity to spread to other sites even before 
diagnosis. Later Spectrum theory emerged and stated that exact meaning 
of metastases to distant sites was unclear. Hence advised both systemic 
and local therapy.  
 
STEPS IN METASTATIC PROCESS 
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Lang et al described three theories  
 
1. Parallel evolution, which says that circulating tumor cells present 
in the tumor is the cause for the metastases during tumorigenesis 
even before the development of the intact primary tumor.  
2. Gene expression profile theory says that potential for metastases is 
an inherent property genetically present in breast cancer patients 
during early stages 
3. Stem cell model says that metastatic potential of breast cancer or a 
specialized tumor initiating cancer cells. 
 Danna et al defined the concept of surgery in metastatic breast 
cancer by the theory of immune-suppression, which is reversible by the 
surgical removal of primary tumor. The first study in evaluating the 
treatment of metastatic breast cancer was by Khan et al in 2002, which 
was a retrospective study, which showed survival benefits. 
 
Survival benefit? 
 
 Question to be answered before initiating the treatment. 
 At present survival for visceral metastases is 6 months, nodal 
disease is 18 months, bone only disease is 3-4 years. 
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 In Khan et al study which reviewed NCDB, 3 years survival was 
24.9% for the whole group. Survival for total Mastectomy 31.9 months, 
partial mastectomy 26.9 months, no surgery 19.3 months . 
 
 There are several studies which showed survival benefit like 
Rapids et al, Gnerlich et al, Blanchard et al, McGuire et al , Babiere et al 
, Neuman et al, reported trends towards increased survival. But it was not 
statically significant.   
 
Should lymph node dissection be done? 
 
 The exact details are not reported not so far in most of the reviews.  
When the logic of improving the survival applies to removal of the 
primary, the same can be applied to ALND. Hence patient under going 
total Mastectomy can be given the benefit of ALND. NCDB conclude 
that ALND can be a contributing factor for survival with total 
mastectomy but it is an independent prognostic factor. Studies evaluating 
the benefit of ALND are Rapids et al, McGuire et al and Neuman et al. 
All these studies showed some survival benefit and advised ALND as a 
part of treatment approach.  
Negative margin be attempted? 
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Even though negative margin is the fundamental concept of 
oncology, there is a lack of data towards the role of negative margin 
resection in metastatic breast cancer. The studies evaluating this are 
Rapids et al, McGuire et al and Khan et al. These studies supported the 
need for negative margins based on the review, which showed five-year 
survival of 27% for negative margin, 16 % for positive margin and 12 % 
for unknown margin. Hence it will be better to give negative margin.  
 
When to operate?  
 
 When the decision of loco-regional treatment is offered, then the 
timing of the surgery is to be decided. Based on the review of articles 
showed that surgery may be done after three months of initial 
diagnosis/chemotherapy improved progression free survival. The time 
gap between diagnosis/ chemotherapy makes the oncologist to study the 
behavior of the disease. Studies favoring this are Babiere et al, Neuman 
et al, and Rao et al.  
 
Prospective Trials 
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 The MF 07-01 9(NCT00557986) is phase 3 RCT that compares 
metastatic breast cancers patients at presentation who receive loco 
regional treatment Vs no treatment and to assess the overall survival 
benefit, which was activated in 2007. Short interim remits in ASCO 
2010 shows no evidence for surgery. Similar NCT 00193778 study from 
India familiar to show such benefit.  
 
 The current evidence is not enough to use surgery for primary 
MBC. However there is subset of patients who may be offered loco-
regional treatment such as surgery to maximize survival. 
 
CONCURRENT CHEMOIRRADIATION  
 
 There is no enough dsatafavouring concurrent chemoirradiation in 
locally advanced breast cancer and metastatic breast cancer ,but there are 
studies favouring concurrent chemoirradiation in breast conservation 
surgery even though not practiced much.Studies favouring concurrent 
chemoirradiation are the following. 
 
 Study1: Argangelia et al did randomized study using concurrent 
Vs sequential CMF chemotherapy. 
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 Sample size 206 pts,TD 50Gy/20# over 4 wks followed by 10-15 
Gy electron boost following BCS.there was no difference in breast 
recurrence, metastasesfree ,diseasefree ,overall survival in the two 
treatment. all patients completed the total dose of Rt and there was no 
difference in toxicity profile between the two arms ,study showed that 
RT can be delayed for 7 months if margins were negative and considered 
concurrent  CMF as a safe regimen and may be used in patients with 
high risk of local recurrence. 
 
 Study2:Rousse et al study used FNC regimen consisting of Inj 
5FU 500 mg/m2 / Mitoxantrone 12mg/m2/ Cyclophosphamide 
500mg/m2 to sequential FEC regimen consisting of Inj2FU200mg/m2/ 
Epiribicin 60mg/m2/ Cyclophosphamide 500mg/m2. 
 
 Sample size 650 pts RT in node positive breast cancer 
ptspts.There was no difference in DFS or overall survival(3% Vs 7%) 
out these 6 had LRR in concurrent arm and 18 had LRR in sequential 
arm. 
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 Study3: Tolenado et al studied Arm –A sequential chemo +RT, 
Arm B concurrent chemo irradiation using FNC regimen consisting  Inj 
5FU/Mitoxantrone/Cyclophosphamide. Sample size 214 pts,local control 
was superior in concurrent arm but toxicity was more like subcutaneous 
fibrosis/ telangiectasia /skin pigmentation /breastatrophy.but there was 
no difference in Grade II skin reaction/breast pain/lymphedema 
Study4: Calais et al similar to Rousse et al study .Toxicity was more, LC 
was good/LRR was low. 
 
 Study5:Bellon et all: was prospective single arm study which 
showed good local control in high risk group patients with  
le received concurrent CTRT 109 ptsVs 426 pts received sequential RT, 
local control and locoregional relapse was lesser in CTRT arm ,these 
studies did not use Adriamycin and taxanes. 
 
 Study7:Goyal et al studied using Bevacizumab in 
combinatconcurrentCMFand lesser dose of RT. 
Study:Rerospective study from Yaion with whole breast RT Vs RT alone 
there was no difference in grade III reactions/no fatigue of RT/RT 
fibrosis/ pneumonitis / lymphedema between the two arms.  
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HYPOFRACTIONATED WHOLE BREAST IRRADIATION  
 
 It is growing trend at present which involves delivering higher 
dose per fraction with in a short period of time to a biologically 
equivalent dose .START Trial A -1-( pT1-3a pN0M0)-TD:50 Gy25#Vs 
41.6Gy or 39Gy in 13# of 3.2Gy or 3.0Gy over 5weeks after surgery. 
Over all treatment time was kept constant in all three arms including 
SCL& Axilla. Primary end point was LRR .LRR at 5 yrs was 3.6% for 
50 Gy/3.5% for 41.6Gy/5.2% for 39 Gy.START B Trial- (pT1-3a pNo-1 
M0)-TD 50Gy25#/40Gy 15# of 2.67 Gy over 3 weeks .Here over all 
treatment time was not consistent.LRR at 5 yrs was 2.2 % for 40 
Gy/3.3% for 50 Gy. Whelan et al study after BCS randomized to TD:50 
Gy @25# vs 42.5 Gy@ 16#.LRR at 10 yrs was 6.7% for 50 Gy 25 
#/6.2% for 42.5 Gy 16 #. 
 
 ASTRO 2011 concluded that hypofractionated  whole breast 
irradiation is equivalent to conventional irradiation who meet the 
following criteria 1)50 yrs and above 2)pathologicT1-T2 N0 treated with 
lumpectomy 3)patient not receiving chemotherapy 4)minimum and 
maximum dose along central axis not <93% and not >107%.heart should 
be excluded from treatment fields during planning hypofractionated 
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RT.RTOG 1005 is phase III study on hypofractionated RT.Taking 
age/comorbidities/distance of RT facility in to consideration 
Hypofractionated RT may be offered to these patients. Accelerated 
Partial Breast Irradiation : 
 
 Even though whole breast irradiation is the standard of treatment 
for BCS patients APBI is an alternate approach which can shortern 
treatment time ,there by more easier for patient,easier delivery of 
radiation and chemotherapy ,also reduces the treatment cost. 
 
 The concept behind this approach is that much of recurrences 
occur at near the operated site. 
 
 This modality includes multicatheter interstitial implants which is 
placed around the operated site,  Mammosite  technology which uses 
single ballon catheter in were in a radiation source is afterloaded at the 
operated site ,external beam conformal partial breast irradiation and 
intraoperative single dose irradiation. 
 This modality has not yet under a randomized study to prove it is 
equivalent  to whole breast irradiation . The current study under trail is  
NSABP-39/RTOG-0413 which allows one of three APBI techniques. 
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 Multicatheter Interstial Techniques: This modality includes tumors 
< 3 cm after lumpectomy,negative margins,0-3 nodes positive,no 
ECE.Dose LDR APBI-45 Gy in 3.5 t0 5 days or HDR APBI 34 Gy in 10 
BD # with in 5 days.No significant adverse effects was noted,No 
statistically significant ipsilateral breast recurrences, or 
LRR,OS,DFS.Studies evaluating APBI are Kuske et al , Vicini et al 
,Arhur et al ,Wazer et  a , 
 
 Mammosite:More extensively used in America,this contains a 
catheter with a central ballon inflated at the lumpectomy site,the distance 
between ballon and skin is > 5mm or ideally >7 mm,treatment is 
delivered by HDR remote after loading system with 1 cm circumference 
around the tumor.Dose 3.4 Gy at 1 cm twice daily to atotal dose of 34 
Gy  over 5 days.It was said that treatment benefit,cosmetic effect,toxicity 
at 5yrs  using Mammosite was similar to other forms of APBI. 
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APBI (Accelerated Partial Breast Irradiation) 
 
External Beam Conformal Radiation. 
 At present over 70 percent of breast cancer patients being treated 
with 3D-CRT which is totally non invasive with homogenous dose 
delivery and distribution.Dose 38.5 Gy at 3.85 Gy/# delivered daily CTV 
included operated site + 1-1.5 cm clearance and 5 mm within the skin 
surface and chest – lung interface. 
 
 Intraoperative Accelerated Partial breast Irradiation:radiation dose 
is delivered  using single intraoperative dose to the operative site at the 
time of surgery using intraoperative electrons or intra operative 
photons.Dose-20 Gy. 
 
 ASTRO 2009 consensus for APBI-patients > 60 yrs/node 
negative/invasive ductal tumors <2 cm/negative margins/ER+/no LVSI.   
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Bone metastasis 
 
 Bone is the most common site of metastatic disease in the breast 
cancer and affects up to 70% of women with metastases. Matastasis 
occurs mostly in the axial skeleton. 
 
 Aim of Of treatment in bone metastasis is avoid skeletal related 
events.median survival after bone metastasis is 19-25 months. if a 
pathological fracture occurs it is reduced to 12 months. 
 
 Sometimes survival may prolonged with good risk factors like low 
grade tumours, bone disease at initial presentation, long disease free 
survival, hormone receptor positive . Bone-only disease has a better 
prognosis than disease associated with visceral involvement.   
 
 Treatment for metastatic breast cancer with bone metastasis is 
mainly hormone therapy therapies and bisphosphonates Radiotherapy 
plays a major role in the treatment of bone metastasis as a palliation. . It 
is of particular benefit for those patients with painful bone disease or 
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spinal cord compression and even in the face of a large burned of 
metastatic disease due to the high response rate and low toxicity. 
 
EFFECTS OF RT ON BONE: 
 
 The majority of bone destruction is meditated by osteoclasts, 
which are in turn influenced by humoral factors released by thetumor. 
Malignant stimulation of the RANK signaling pathway increases the 
osteoplastic activity . New bone formation is predominantly reactive ,but 
may be exuberant, generating new bone that often lacks the strength of 
normal lamellar bone.  
 
 Pain may be either nociceptive (mediated by prostaglandins, 
substance P, and other cytosine’s) or neuropathic (as a result of bone 
destruction and increased resorption, peri-osteal irritation and nerve 
entrapment). The mechanism by which radiotherapy improves pain is not 
clearly understood.  
 
Progression  
 
 Either an increase in worst pain score of 2 or more at the treated 
site without reduction in analgesic use or an increase of 25% or more in 
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daily oral morphine. Equivalent compared with baseline without a 
reduction in baseline worst pain score.  
 
Fraction in the treatment of localized bone metastases  
 
 The largest single randomized study – the Dutch bone metastasis 
study (DBMS) (13) – randomized only 29% of eligible patients. All of 
the randomized studies included multiple different tumor types, but in all 
cases breast and/or prostate cancer formed the predominant patient 
groups. In the DBMS, 49.7% of the 1157 patients had breast cancer.  
A single fraction of 8Gy delivered for palliation achieves a 60% 
response rate by intention-to-treat analysis. Approximately one-third of 
patients treated have a complete pain response. Overall, mean time to 
response is 3 weeks and mean duration of remission is 18 weeks. Single 
fraction are clearly more convenient for the patient and increase 
treatment capacity for the radiotherapy center. While single fractions are 
commonly employed in the United Kingdom and Canada, fractionated 
regimens such as 20gy in 5 fractions or 30Gy in 10 fractions are the 
norm in the rest of the world. 
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Re-treatment of bone deposits  
 
 Re treatment after a single fraction is recorded for 21.5% of 
patients as compared with 7.4% of those receiving multiple fraction. 
Single-fraction treatment has also been tested against multiple fractions 
in the treatment of neuropathic bone pain, where it has been argued that 
multiple fractions are required to required to reduce tumour mass and 
relive pressure on nerves . 
 
Axial metastasis  
 
Presentation in the descending order in carcinoma breast 
1. Vertebra primarily thorocolumbar 
2. Pelvis  
3. Ribs 
4. Femur 
5. Humerus 
6. Other sites eg.scapula,tibia,skull 
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Spinal metastasis 
 
 30-70% of patients with carcinoma breast has spinal metastasis at 
the time of death 
 
 Pain in spinal metastasis is due to release of local chemical 
mediators subatance P , bradykinin and histamine and due to enlarging 
tumour mass, bone defect leading to pathological fracture /deformity 
kyphosis /scoliosis or both ,nerve root compression due to tumour mass 
,compression of spinal cord due to tumour mass because of tissue 
reaction or fractured fragments 
 
MANAGEMENT OF SPINAL METASTASIS  
 
Class I –no nerve involvement –chemotherapy or local RT 
Class II –involvement of bone no collapse – chemotherapy of local RT 
Class III – neurological involvement –without body involvement –local 
  RT/steroids 
Class VI – vertebral collapse with instability without nerve involvement 
  – surgery 
Class V – vertebral collapse with nerve involvement – surgery 
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 Goals of spinal surgery should include neural decompression, 
spinal stability, correction of spinal deformity 
 
 However with the advent of minimally invasive spinal surgery it is 
concentrating on three main areas , biopsy , replacing bone loss by 
vertibroplasty and kyphoplasty , reconstruction and stabilization through 
endoscopic procedures 
 
MANAGEMENT OF ACETABULAR METASTASIS 
 
Class I –lateral cortex - superior medial walls intact – cemented  THR 
Class II – deficient medial wall – protrusio cup  cemented THR 
Class III – deficient lateral and superior wall – protrusion cup with 
fixation with cemented THR 
 
Class IV – solitary metastasis resection of lesion – girdle stone saddle  
  prosthesis of custom made prosthesis  
Mirel’s scoring system for appendicular metastasis  
 
Location –peritrochantric (3) – lower extremity (2) – upper extremity(1) 
Lesion type – lytic         (3)  -mixed: lytic & blastic (2)- blastic (1) 
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 Amount of cortical loss ->2/3    (3)  –   1/3 to 2/3  (2) -     <1/3    (1) 
Pain  - functional  (3)  – functional, moderate(2) – moderate        (1)  
A score of 8 and above is indicative of surgery 30 -50 %of loss in bone 
mineral density has to occur to be picked up on a plain X-ray film >50% 
loss in thickness of cortical bone in plain X- ray signifies impending 
fracture and osteolytic lesion >2.5cm is considered significant  
 
CHARESTESTRICS OF METASTSTIC TNBC 
 
 TNBCs have a poor prognosis in the adjuvant setting, 
characterised in particularly by early recurrence compared to other 
subtypes of breast cancer. This occurs despite a high sensitivity to (neo) 
adjuvant chemotherapy. Although cancers that have a pathologic 
complete response (pathCR) to neoadjuvant chemotherapy have a good 
prognosis, those cancers that donotachive a path CR have a marked poor 
prognosis sith frequent and early relapse.  Distance disease free survival 
at 4 years was 87% for those who had a path CR compare to 69% in 
those who didnot.  
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 A vast majority relapses from TNBC occur in the first 5 years 
following prognosis the reasons for poor prognosis in the metastatic 
setting are multi factorial. This reflects the lack of targeted therapies for 
TNBEC and the highly proliferative nature of TNBC this reflects the 
pattern of metastasis seen in TNBCs characterised by less frequent bone 
and liver metastasis and  more frequent lung and brain metastasis. 
Current evidence suggests that triple negative basal like and non basal 
like breast cancers have similar pattern of metastasis  
 
 Molecular subtype is also predictive for risk of loco regional 
recurrence after these breast conserving surgery and mastectomy  with 
contemporary trastuzumab containing adjuvant systemic therapy the 
outcome of the HER2 enriched group  is now likely to have improved 
,leaving BLBC as the cancer subtype with highest risk of local relapse. 
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LEPTOMENINGEAL METASTASES:  
 
 It is commonly seen with lobular histology of carcinoma  breast  
,it arises mostly from the pia and archanoid space or subarachnoid space 
,spread is due through blood ,direct extension through venous plexus 
along nerves or perineural invasion .Once it reaches the meninges it 
spreads through CSF. Symptoms  will be due to raised ICT ,local 
inflammatory responses like severe headache and vomiting ,focal 
neurological deficits,seizures.Investigation of choice will be Gadalinium 
enhanced  MRI, prognosis is poor ,survival will be 5-7 months. 
 
 Radiotherapy  to craniospinal axis is difficult due to bone marrow 
toxicity. Intrathecal  chemotherapy and systemic chemotherapy is 
advised in these conditions. 
 
INTRA MEDULLARY METASTASES: 
 
 One of the rare presentation  in breast cancer 0.1-6%, overall 
survival 13 months .commonly involves cervical spine. Clinical  signs 
depends upon the level of involvement. Investigation of choice is  MRI 
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(iso intense and nodular on T1 images and pencil shaped hyper intense 
on T2 images .Treatment involves steroids and radiotherapy.In patients 
with stable disease and without leptomeningeal spread surgery can be 
attempted. 
 
EPIDURAL METASTASES: 
 
 The most vascular portion which is the posterior part vertebral  
body is the site of metastases, commonly involves thoracic vertebra(50-
60%),lumbar (30-35%),cervical(10-115%)in proportion to the volume of 
bone marrow . Back pain is the most common symptom ,myelopathy due 
to spinal cord compression , sensory disturbances. Investigation of 
choice will be MRI ,plain X-ray may be useful to see the stability of 
spine . 
 
Goal of treatment  
 
1. preserve neurological function 
2. relieve pain  
3. preserve stability of spine. 
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 Conservative treatment includes inj dexamethasone, radiotherapy 
with one level above and one level  below. Surgery involves  
laminectomy  and spinal stabilization followed by post op RT after 3 
weeks. Surgery may involve anterior or posterior decompression .Recent 
advances in treatment involves procedures like vertebroplasty or 
kyphoplasty .  
 
 “To cure sometimes To relieve sometimes To comfort always .” 
 
TREATMENT 
 
 Carcinoma Breast has been divided into Early stage, Locally 
advanced and metastatic breast cancer.  Treatment options vary 
according to the stage of the disease. The surgical management of breast 
cancer improved a lot for the past 30 years. Inially according to 
Halsteadian principles aggressive surgical management was done by 
Classical radical mastectomy.  
 
 Another hypothesis suggested that the extent of surgical resection 
alone not sidnificantly affect patients outcome and this supported bt 
trials also. As a result administration of poatoperative systemic 
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chemotherapy, hormonal therapy or both become standard practice for 
the majority of the patients. It reduces the rate of recurrence and 
metastasis ,so increases  the  overall survival. So surgery may be 
modified radical mastectomy or breast conservative surgery. 
Neoadjuvant chemotherapy plays a major role in locally advanced breast 
cancer to make the inoperable tumors to operable one. Even in operable 
tumorsneoadjuvant therapy is used before breast concervative surgery. 
 
SURGERY: 
 
 The surgical management of patients is involves both the primary 
tumor and regional lymphatics.  The primary tumor may be managed by 
modified radical mastectomy or Breast conservative surgery .Axilla is 
treated by either axillary dissection or sentinallymphnode biopsy.  
 
CHEMOTHERAPY 
 
SCIENTIFIC RATIONALE for primary systemic chemotherapy 
 
 The role of is primary systemic chemotherapy or neoadjuvant 
chemotherapy was justified by several hypothesis.it indicated that non 
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courative  reduction of tumor cell burden increased the 
proliferaticells.after surgery of the primary tumoue there is an increase in 
the proliferation of remaining tumour cells in the metastatic sites. This 
change occurs even after primary tumour irradiation. Removal of a 
primary tumor exerts its affect over the metastatic sites and causes 
stimulation of  growth following surgical removal or reduction was due 
to soluble growth factor..  
 
 The neoadjuvant chemotherapy helps to decreases the 
micrometastases and prevent cancer growth cyclophosphamide,t 
amoxifen and radiotherapy prior to surgery prevent kinetic alterations 
suppresses tumor growth which inturn may increase the survival. 
  
The Goldie – coldman hypothesis 
 
 As tumor cell population increases, an ever expanding number of 
duly resistant phenotypic variants arise time to spontonous somatic 
mutations  that become more difficult  to eradicate. The resistant cells 
can be minimized by initiating combination of non cross resistant drugs 
when the tumor cells are less in number. when the tumor grows not only 
the number of resistant cases increases and so is the proportion of 
resistants cells in the total cell population.   Resistant phenotypes 
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multiply not only as a results of their own intrinsic growth rates and also 
due to the addition of new mutation.  
 
 Increased proliferation of cells following surgery causes increase 
in the number of resistant phenotypes in the metastasis. Neoadjuvant 
therapy not only stop cell proliferation but also eliminate cells that would 
have been made more sensitive by their kinetic alteration following 
surgery.  
  
Scientific rationale for adjuvant chemotherapy 
 
Skipper and schabelconcept 
 
 They proposed that growth fraction and doubling times of tumors 
differs in from those in micro metastasis. So later they may well respond 
to adjuvant chemotherapy. After the primary surgery with decrease in 
tumour burden may alter the growth charecteristics and increase the 
chemosensitivity of the adjuvant treatment. It justifies the adjuvant 
chemotherapy. 
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Adavantages of neoadjuvant chemotherapy 
 
1. Chemotherpay response can be assessed in vivo 
2. Downstaging of the primary tumour and nodes. 
3. Feasibility of surgery is enhanced due to reduction in tumour 
growth  
4. Response to the chemotherapy act as a prognostic factor for long 
term survival. 
 
Disadvantages of neoadjuvant chemotherapy 
 
1. It delays the effective primary therapy 
2. Imprecise clinical and radiological staging 
3. Loss of prognostic significance of axillary nodal statusUnknown 
relevance of surgical margin 
4. Large no of drug resistant cells may present 
5. Response to the primary tumour may not correlate with the 
response to the micrometastasis 
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 Antracycline and Taxane based chemotherapy regimens are 
currently the most effective agents for women with locally advanced and 
operable breast cancer. The most recent Eastern Breast Cancer 
TraialistsGroup(EBCTCG)results published in 2005 concluded that 
treatment with approximately 6 months of anthracycline-based 
chemotherapy with a regimen such as 5-fluorouracil, Adriamycin, and 
Cyclophosphamide (FAC) reduces the annual breast cancer death rate by 
about 38% for women younger than 50 years of age and by about 20% 
for those of age 50 to 69.  
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This meta-analysis also confirmed a moderate but highly 
significant advantage for anthracycline-based regimens (those including 
Adriamycin or Epirubicin) to regimens consisting of Cyclophosphamide, 
methotrexate, and 5-fluorouracil (CMF) in trials involving more than 
14,000 patients. The Cancer and LeukaemiaGroup(CALGB) 9344 study 
randomized 3121 women who had node-positive breast cancer to four 
cycles of AC or four cycles of AC followed by four cycles of Paclitaxel 
(AC-T) with dose-escalated doxorubicin. The addition of Paclitaxel was 
associated with significant 5-year DFS (70% versus 65%) and OS (80% 
versus 77%) benefits. 
 
 
 Pacitaxel   200mg/m2 IV over 3 hrs on day 1, repeat cycle every 
21 days.
 
 Docetaxel  75 mg/m2IV on day 1,reapeat cycle every 21 days. 
 Paclitaxel1 bevacicizumab -  Paclitaxel:90 mg/m2IV on days 
1,8,15.
 
 Bevacizumab;(Monoclonal antibody) anti vegf –antibody  10 
mg/m
2
 on days 1 and 15,repeat Cycle every 21 days.
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CHEMOTHERAPY RESPONSE ASSESSMENT  
 
 Tumour response assessment usually occurs 8-12 weeks after the 
starting of chemotherapy and comprises a summary of radiological and 
clinical responses, symptomatic benefit (including any improvement in 
performance status) balanced against toxicities of treatment. 
Radiological response (determined by response evaluation criteria in 
Solid Tumours (RECIST) criteria, is an improvement guide to the 
clinician in deciding whether to continue or change therapies.  
 
 While objective tumour responses (i.e., tumour shrinkage by more 
than 30%; Table @) set the standard user in clinical trials to judge the 
efficacy of chemotherapy, stabilisation of disease by RECIST criteria 
with a symptomatic benefit is an equally important endpoint. In patients 
with non-measurable disease, (e.g., bone-only disease) treated with 
chemotherapy, serial tumour markers together with symptomatic benefit 
are important indications of response to treatment. 
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Miller-Payne histological criteria for grading response to solid 
tumours to chemotherapy in breast cancer. 
 
Grade  Description 
1 No change  
2 A minor loss up to 30% loss 
3 Between  30% and 90% reduction in tumour cells 
4 
A marked disappearance of tumour cells 
more than 90% loss of tumour cells 
5 
No malignant cells identifiable in sections from the 
site of the tumour; only vascular fibroelastoticstroma 
remains often containing macrophages. However, 
ductal carcinoma in situ (DCIS) may be present 
 
RADIOTHERAPY 
 The worldwide trend to be less radical treatment in the 
management of Carcinoma Breast has led to increasing role of 
radiotherapy in this disease. The first major use of radiotherapy in breast 
cancer was adjuvant to radical mastectomy. As the risk of local 
recurrence after mastectomy was 10 to 15% it was hoped that 
prophylactic radiotherapy would decrease this. Fletcher has also stressed 
74 
 
the judicious use of postoperative radiotherapy since the probability of 
control of gross local or regional recurrence from breast cancer is less 
than 60%. Post operative radiotherapy helps to decrease chances of local 
recurrence and increase local control & hence increase survival. 
 
 The technique of breast irradiation has evolved from use of 
conventional two dimensional planning with and without using wedges 
to 3 D conformal radiotherapy and intensity modulated radiotherapy 
(IMRT). Standard opposed tangential fields with appropriate use of 
wedges to optimize dose homogeneity remain the most commonly 
employed method for delivery of whole breast irradiation. These 
approaches include multicatheter interstitial implants placed around the 
excision cavity, single balloon catheter that can be afterloaded with a 
central radiation source (MammoSite) which is placed into the excision 
cavity, external beam conformal partial breast irradiation, and 
intraoperative single-dose irradiation. 
 
 Even after mastectomy and systemic therapy occult disease may 
remain in the chest wall and or regional lymph nodes. The residual 
disease may serve not only as a source of potentially morbid loco-
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regional recurrence but also an important reservoir from which distant 
metastases may be seeded after the initial elimination of  distant disease 
by systemic therapies. Therefor postmastectomy radiation therapy 
(PMRT) is an essential part of the treatment. Postop RT decreases risk of 
loco regional recurrence by treating residual microscopic disease that has 
spread beyond margins of surgical resection. The term local recurrence 
means the evidence of disease appearing in scar site or skin belonging to 
breast anatomical area or nodal drainage areas after adequate primary 
management. 
 
Loco-regional failure can occur in the following sites 
1. Ipsilateral chest wall/ Mastectomy Scar 
2. Axillary Lymph nodes/Soft tissues 
3. Supra/Infraclavicular Lymph nodes 
4. Internal mammary Lymph nodes 
 
Types
 
1. Skin 2. Scar 3. Nodal 4.Combined. 
 Local skin recurrence may be nodular or inflammatory. Nodular 
may  be solitary or multiple occurring most frequently in skin or 
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subcutaneous tissues in and around mastectomy scar. Small nodules are 
usually asymptomatic while larger ones can cause pain, itching or 
ulceration. In advanced situation confluent nodules may encircle chest to 
form cancer encuirasse.  
 
The inflammatory type also called as erypeseloid is less common. 
The lesion appears as diffuse reddening of skin associated with slight 
induration and increase in local temperature. Patients with this type of 
recurrence have poor prognosis and usually die of widespread metastatic 
disease within a short span of time. The scar recurrence is usually in the 
form of nodules or ulcers. Lymph node recurrence takes the form of 
nodules growing and getting fixed and ulcerating producing 
lymphedema of arm and painful limitation of arm movements. 
 
Principles Of Concurrent chemoradiation:  
 
Concurrent chemoradiation has produced important improvements 
in treatment outcome. Randomized clinic trials show improved local 
control and survival through the use of concurrent chemotherapy and 
radiation therapy for patients with high-grade gliomas and locally 
advanced cancers of the head and neck, lung, esophagus, stomatch, 
rectum, and anus.   
77 
 
 The first is mechanism is radiosensitization.. The underlying 
concept is that the observed effect of using chemotherapy and radiation 
concurrently is greater than simply adding the two together synergy 
cannot be determined simply by normalizing the radiation cell-survival 
curve for drug-induced cytotoxicity  
 
A second proposed reason to combine radiation and chemotherapy 
is to realize the benefit of improved local control radiation along with the 
systematic effect of chemotherapy; a concept called spatial additivity.  
 
 Although concurrent chemotherapy has improved survival and 
organ conservation, further advances are limited by the toxicity of 
treatment. For example, in the curative treatment of locally advanced 
head and neck cancer with chemoirradiation. It is now standard toplace a 
gastrostomy tube prophymucositis that they are unable to maintain 
adequate nutrition orally. The toxicity of treatment resukts from the 
relative lack of specificity of both radiation and chemotherapy for cancer 
cells as opposed to rapidly dividing normal cells.  
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MECHANISMS OF LOCAL RECURRNECE   
1. Extra mechanism is unknown  Proposed theories include 
2. Seedling from peripheral extensions of tumour  
3. Implantation from vessels that ooze blood or lymph containing 
tumour emboil. 
4. Retrograde movement of tumour cells to edge of the wound 
5. Immunological factors.   
 
 Chest wall is the most common site of recurrent disease, 
accountiong for two-thirds to three-quarters of all local-regional 
recurrences.  
 
RISK CATEGORIES FOR LOCOREGIONAL RELAPSES 
AFTER MATECTOMY AND AXILLARY CLEARANCE  
 
RISK 
CATEGORY  
LOW INTERMEDIATE HIGH 
RISK <10% 10-20% >20% 
TUMOUR 
STAGE  
T1-T2 T1-T2 T3-T4 
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NO OF 
AXILLARY 
NODES  
0 1-3 >3 
GRADE 1-2 3  
VASCULAR 
INVASION  
- +  
HISTOLOGY  DUCTAL LOBULAR  
 
RISK OF AXILLARY RUCURRENCE 
 
1-3 +VE LN (10YR-LRF)  
2-5 LN dissected  7%  
6-10 LN 5% 
>11LN 1.5% 
>4 +VE Ln (10yr-lrf)  
4-5ln DISSECTED 12% 
6-10  8%  
>11 LN 6% 
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 Early breast cancer Trialists’  collaborative group and 2002 
Cochrance review have shown that postoperative radiotherapy decreases 
recurrence rates by two their.  Post operative RT decreases recurrences 
rates in stage 1 by 5%, stage 2 by 10% and stage 3 by 10 to 15%. 
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REVIEW OF LITERATURE 
 
ROLE OF SURGERY 
Prospective Trials 
 
 The MF 07-01 9(NCT00557986) is phase 3 RCT that compares 
metastatic breast cancers patients at presentation who receive loco 
regional treatment Vs no treatment and to assess the overall survival 
benefit, which was activated in 2007. Short interim remits in ASCO 
2010 shows no evidence for surgery. Similar NCT 00193778 study from 
India familiar to show such benefit. 
 
The current evidence is not enough to use surgery for primary 
MBC. However there is subset of patients who may be offered loco-
regional treatment such as surgery to maximize survival. 
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ROLE OF RADIOTHERAPY 
Review of literature 
 
 .A study from the Centre René Huguenin (Paris, France), loco 
regional radiotherapy was significantly associated with increased 
survival on multivariable analysis. In this study they were rarely used 
surgery as a primary treatment in metastatic breast cancer. They used 
locoregional radiotherapy as a main modality. The conclusion in that 
trial was locoregionalradiotherapy ,may be an alternate modality for 
surgery in metastatic breast cancer with leess morbidity 11 
 
 Another study  from the Institute Gustave-Rousse (Paris, France), 
239 women with stage IV breast cancer received loco regional treatment, 
either with radiotherapy alone or surgery with or without radiotherapy. 
In this study there was  no significant difference in overall survival was 
observed, again it showed  that radiotherapy, without surgery, was an 
adequate loco regional treatment metastatic breast cancer of women. 
 
Retrospective Studies 
 
 A trial from Tata Memorial Hospital (Mumbai, India) was 
initiated in 2005.
]
 In this trial, chemotherapy is given before any 
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locoregional treatment. Preliminary results reported that 72% of patients 
in the locoregional treatment arm are free of disease progression 
compared with 61% in the observation arm. On multivariable analysis, 
locoregional treatment is a significant factor for progression-free 
survival.  
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THEORETICAL ADVANTAGES OF LOCOREGIONAL 
TREATMENT OFTHE PRIMARY DISEASE BY SURGERY  
 
1. The removal of the intact primary tumor has been 
hypothesized to potentially reduce hematogeneous seeding by 
micrometastatic populations since local disease may serve as a 
hub of tumor stem cells  
2. Another theoretical advantage of loco regional treatment in the 
setting of stage IV disease can reduce levels of circulating tumor 
cells that improved disease response and survival, and longer time 
to progression are associated with a lower number of circulating 
tumor  
3. .Some biologists contend that tumor dissemination can 
compromise the immune system. The primary tumor can produce 
immunosuppressive factors that may help cancer cells avoid 
eradication by the immune system. In this context, surgical 
resection can reduce tumor load and lessen harmful immuno-
suppression.  
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o A Theoretical Disadvantage of local therapy is based on the 
hypothesis that the primary local tumor can secrete substances that 
inhibit new blood vessels that support tumor growth.  
o Removal of the primary disease can induce an angiogenic surge 
and promote the progression of metastases.  
o Some believe that trauma induced by surgical intervention and 
general anesthesia can generate cytokines that stimulate neoplastic 
proliferation and compromise the integrity of the immune system.  
 
Advantages of radiotherapy 
Radiotherapy is a scientific surgery 
 
1. Non invasive 
2. No risk of anaesthesia 
3. No risk of comorbidities 
4. Can be given in patients with disseminated disease. 
5. Skin is the best dressing and protection of the tumor  which is not 
disturbed . 
6. Cost effective , no need of hospital admission  
 
 
86 
 
AIM OF THE STUDY 
 
 Aim of this retrospective study is to evaluate the role of loco 
regional treatment such as local radiotherapy and surgery in the 
management of patient with  metastatic breast cancer. 
 
METHODS AND MATERIALS  
 
Study design: This study is a retrospective study to evaluate the 
role of 11 loco regional treatment such as radiotherapy and surgery  in 
Metastatic Breast Cancer. 
 
Inclusion and exclusion criteria  
Inclusion criteria    
In our retrospective study we reviewed female patients with metastatic 
breast cancer registered at cancer Institute were analyzed from the year 
2003 to 2008. 
  
 
Inclusion criteria for this study were the following  
Study setting  
 All medical records of female patients with metastatic breast 
cancer registered at cancer Institute  from the year 2003 TO 2008  and 
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who fulfil the inclusion and exclusion criteria of the study were reviewed 
and included in this study  
 
Duration of the study  
patients from the year 2003 to 2008  
 
SAMPLE SIZE:  
 
195 patients (120 patients underwent loco regional treatment 75 
no treatment)  
 
TREATMENT PROTOCOL  
 
 All patients were treated with chemotherapy with or without 
concurrent radiotherapy. After six months of initial treatment response 
was assessed and decision regarding surgery was taken. Radiotherapy 
was given concurrently with chemotherapy. 
 
Whole Breast  Irradiation 
 
Treatment volume  
 
 The areas treated generally include the whole breast with or 
without  supraclavicular, axillary regions. The entire breast and chest 
wall are included in the irradiated volume.  The upper margin of the 
88 
 
portals should be placed at the head of the clavicle to include the entire 
breast. The medial margin should be at or 1cm over the midline.  The 
lateral posterior margin should be placed 2cm beyond all palpable breast 
tissue. Which is usually near the mid-axillary line. The inferior margin is 
drawn 2 to 3 cm below the inframammary fold.  In patients treated with 
6-MV or lower energy photons with side tangential fields.  
 
 
 
 The entire ipsilateral breast should be encompassed. Conventional 
field borders are used. BREAST is treated using two tangential fields, 
medial and lateral tangents. Superior border is kept at second intercostal 
space.  Medical border is at midline or matched with internal mammary 
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field when used. Lateral border is kept at midaxillary line. Inferior 
border is at 2 cms below opposite inframammary fold. 
 
 
SUPRACLAVICULAR FIELD 
 
 Supraclavicular nodes are ususlly encompassed, with a single 
anterior oblique photon field angled slightly away from the spinal cord.  
The medial border is placed at the insertion of the clavicular head.  The 
lateral border is placed to include approximately one-third of the 
humeral head. The inferior border is the inferior border of the clavicle or 
the superior border of the chest wall field. The superior border is set at 
the thyrocricoid groove. A humeral head block is added to block the 
humeral head and acromioclavicular join 
54
 
 
 To avoid the problem of hot spot whoile matching supraclavicular 
and chest wall fields following methods are used. Angling the foot of the 
treatment couch away from the radiation source to direct the tangential 
fields inferiorly so that superior edge of these beams line up perfectly 
with inferior border of supraclavicular field. We canalso used the three 
field single isocentre technique or Hanging block technique. Half beam 
block can also be used.  
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INTERNAL MAMMARY FIELD 
 
 The internal mammary chain lies beside the sternum, generally in 
the first through the third intercostal space, althoiugh the depth may 
vary. Various methods of encompassing the ionternbal mammary chain 
have been described, including extended tangent fields, partially wide 
tangent fields and matching electron and photon fields. But prophylactic 
internal mammary nodal irradiation is not recommended even in medial 
quadrant tumors.
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POSTERIOR AXILLARY BOOST  
 
 The dose provided to the axillary nodes through the 
supraclavicular/axillary field can sometimes creat suboptimal dose 
distributions to deeper lying level 3 axillary nodes. If coverage is 
suboptimal, the dose can be supplemented with a posterior axillary field. 
The field is set up opposed to the supraclavicular/axillary field. The 
medial border of this field is drawn to allow 1.5 to 2 cm of lung. If the 
inferior border is at the same level as the inferior border of the 
supraclavicular field, the lateral border just blocks falloff across the 
posterior axillary fold, the superior border splits the clavicle, and the 
superolateral border shields or splits the humeral head. 
54 
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DOSE 
 
 Most commonly employed dose schedule is 40-45Gy in 22- 25 
fractions at conventional 180cGy daily for 5 weeks 
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DOSE VOLUME HISTOGRAM 
 
 
FOLLOW UP 
 
 Subsequently patients were followed up monthly for the first year 
and once in threemonths for a period of five years from date of 
completion of radiotherapy after 5 years yearly follow-up was done  
 
ASSESSMENT TOOLS  
 
Medical records were reviewed for the following factors. 
1. age at diagnosis 
2. laterality  
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3. histology of the tumor 
4. clinical and pathologic size of the primary tumor 
5. lymph node status 
6. hormone receptor status 
7. her 2 over expression 
8. location and number of metastases mode  
9. date of surgical treatmen 
10. t, margin status,  
11. use of radiotherapy 
12. systemic therapy 
13. The time of death 
14. the time of last  review among alive patients 
15. Patients with metastatic Breast cancer excluding brain metastasis 
at presentation were included. 
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Patients baseline charecteristics 
 
FACTOR NO OF CASES SURVIVAL PERCENTAGE
1 yr 3 yr 5 yr 10 yr
All cases 188 78 43 35 30
Pre Menopause 65 77 43 35 26
Post menopause 112 80 41 33 31
ER negative 55 75 40 36 34
ER positive 84 82 54 42 37
PR negative 66 76 41 33 32
PR positive 66 82 56 45 39
Her2 negative 31 94 68 61 58
Her2 positive 14 79 36 36 36
Metastasis 1 31 90 65 55 50
Metastasis 2 68 82 53 43 37
Metastasis 3 18 61 22 17 10
Metastasis 4 20 85 55 50 45
Metastasis 6 38 68 21 13 7
Metastasis 7 3 67 0 0 0
Metastasis 8 7 71 14 14 14
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MENOPAUSAL STATUS 
 
0
20
40
60
80
100
120
premopausal postmenopausal 
NO OF PATIENTS
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Most of the patients in this study were  premenopausal. 
 
ESTROGEN RECEPTOR STATUS 
 
0
10
20
30
40
50
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70
80
90
Estrogen +ve Estrogen-ve
HR status
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Estrogen receptor status No of patients 
ER+ve 84 
ER-ve 56 
Status not known 55 
 
PROGESTRONE RECEPTOR STATUS 
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PR STATUS NO OF PATIENTS 
PR+VE 66 
PR-VE 66 
 
Results 
Tumour stage of the patients  
 
Out of 195 patients 118 had T3 tumor size and 37 pts had T4 
disease ,remaining 36 patients comes under T1,T2,T0 
 
Tumor size No of pts 
T4 37 
T3 118 
T1,T2,T0 36 
 
99 
 
T 4 T 3 T 1 , T 2 , T 0
37
118
36
SERIES 1
 
 
Most common tumour stage was  T3 
 
NODAL STAGE OF THE PATIENTS  
 
24% of the patients had N3 disease and 31 had N2 stage , 36% of 
them had N1 and 9% 
 
Had N0 disease  
NODAL STAGE PERCENTAGE OF PATIENTS 
N3 24 
N2 31 
N1 36 
N0 9 
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Most common nodal stage was N1 
 
 
Out of 195 pts 86 pts are hormone receptor positive and in 109 pts 
the details of  Receptor status not known. 
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Receptor status No  
HR positive 86 
HR not known 109 
 
Her2neu status  of the patients 
 
 
 
Graph:Precentage of patients with left and right sided tumours 
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54%
46%
0% 0%
 
Most common sides  
In this study right sided tumours were found to be more common 
than left side tumours. 
 
Incidence of bone metastasis 
 
Out of 195 patients 33 patients (32%) had single bone metastasis 
and 70 patients (68%) had  multiple bone metastasis 
 
NO OF BONE METASTASIS NO OF PATIENTS 
SINGLE METS 33 
MULTIPLE METS 70 
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Graph  : Percentage of pts with single and multiple bone metastasis 
 
LIVER AND LUNG METASTASIS 
 
out of 195 total patients 18 patients (9%)  had liver metastasis and 
21 patients  (11%) had lung metastasis ,two patients (1%) had both liver 
and lung metastasis. 
 
Site of metastasis No of patients 
Liver  18  
Lung  21 
Both liver and lung 2 
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Patients with multiple metastasis  
 
 
40 patients (21%) had multple visceral and nonvisceral metastasis 
excluding brain which is not included in the study. 
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Total no of pts 195 
Multiple mets 40 
 
code  for various treatment options 
 
 
1. code  for various treatment options  
2. chemoirradiation  (RT+CT) 
3. chemotherapy +surgery (CT+SX) 
4. Chemoirradiation + surgery(CT+RT+SX) 
5. Chemotherapy only (CTonly) 
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6. Radiotherapy only (RT only) 
7. chemotherapy +hormone therapy (CT+HT only) 
8. radiotherapy +hormone therapy (RT+HTonly) 
9. chemotherapy+radiotherapy+hormone therapy (CT+RT+HT) 
 
Various treatment OPTIONS 
 
 Out of 195 patients with Metastatic Breast Cancer, 
 74 patients received chemoirradiation. 
 37 patients received chemoirradiation and then underwent surgery.  
 44 patients received chemotherapy alone.  
 3 patients received radiotherapy alone.  
 2 patients received chemotherapy and surgery. 
 
Total no of patients 195 
chemoirradiation 74 
CT +SX 37 
CT 44 
RT 3 
SX 2 
 
107 
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CHEMOIRRADIATION 
 
Out of 195 patients  74 patients received chemoirradiation .  
 
 
 
RESULTS  
  In patients receiving CT+RT survival at the end of 1 yr was 
(89%) 3 yr (58%) 5 yr (46%) 10 yr,(42%). 
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CHEMORADIATION AND SURGERY 
 
 Out of 195 patients 37 patients received chemoirradiation   
and then underwent surgery. 
37
158
CT +SX other patients 158
 
 
RESULTS; 
In patients receiving CT+RT + surgery at the end of 1 yr was 
(97%) 3 yr (80%) 5yr(70%) 10 yr,(71%).  
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CHEMOTHERAPY  
 
Out of 195 patients with Metastatic Breast Cancer 
44 patients received chemotherapy alone.  
44
151
received chemotherapy  44 other patients 151
 
RESULTS 
In patients receiving CT only at the end of 1 yr was (60%) 3 yr 
(5%) 5yr(2%) 10 yr,(0%).  
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RADIOTHERAPY 
 
Out of 195 patients with Metastatic Breast Cancer 3  
patients received radiotherapy alone.  
 
 
 
RESULTS: 
 In patients receiving RT only at the end of 1 yr was (67%) 3 yr 
(33%) 5yr(33%) 10 yr,(33%).  
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CHEMOTHERAPY AND SURGERY 
 
OUT OF 195 PATIENTS RECEIVED chemotherapy and surgery 
 
2
193
0
.
patients received chemotherapy and durgery other patients 
 
 
Hormonal therapy 
 
 8 patients received hormonal therapy alone. 
 12 patients got chemotherapy and hormonal therapy 
 5 patients received radiotherapy and hormonal therapy. 
 6 patient srecivedhemoirradiation and hormonal therapy  
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NO OF PATIENTS 195 
HT 8 
CT+HT 12 
RT+HT 5 
CT+RT+HT 6 
 
HORMONAL THERAPY 
 
 Out of 195 patients with Metastatic Breast Cancer 
 8 patients received hormonal therapy alone. 
patients received hormonal therapy other patients 
 
In patients receiving HT only at the end of 1 yr was (50%) 
 3 yr (13%) 5yr (13%) 10 yr,(13%).  
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Chemotherapy and hormonal therapy 
 
 Out of 195 patients with Metastatic Breast Cancer12 patients got 
chemotherapy and  
 
 
hormonal therapy 
 
In patients receiving CT+HT at the end of 1 yr was (58%) 3yr (8%) 
5yr(0%) 10 yr,(0%).  
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Radiotherapy and hormonal therapy 
 
Out of 195 patients with Metastatic Breast Cancer  
5 patients received radiotherapy and hormonal therapy 
 
. 
 
 In patients receiving RT + HT at the end of 1 yrsurvival  
 was (50%) 3yr(0%) 5yr(0%) 10 yr,(0%).  
 
Chemoirradiation and hormonal therapy. Out of 195 patients with 
Metastatic Breast Cancer  6 patientsrecived Chemoirradiation and 
hormonal therapy. 
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00
patients recived chemoirradiation and hormonal therapy. other patients 
 
 
In patients receiving CT+RT + HT survival at the end of 1 yr was (67%) 
3yr(50%) 5yr(0%) 10 yr,(0%). 
 
VARIUOS TREATMENT MODALITIES 
 
39%
23%
19%
2%
1%
4%
6%
3% 3%
CT+RT CT CT+RT+SX RT CT+SX HT CT+HT RT=HT CT+RT+HT
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FACTOR NO OF CASES SURVIVAL PERCENTAGE
1 yr 3 yr 5 yr 10 yr
Treatment modality
0 4 50 25 25 0
2 72 89 58 46 42
3 1 100 100 100 100
5 35 97 80 77 71
6 43 60 5 2 0
7 3 67 33 33 33
8 8 50 13 13 13
9 12 58 8 0 0
10 4 50 0 0 0
11 6 67 50 0 0
 
V Out of 195 patients  74 patients received chemoirradiation and then 
underwent surgery. 
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FACTOR NO OF CASES SURVIVAL PERCENTAGE
1 yr 3 yr 5 yr 10 yr
All cases 188 78 43 35 30
Pre Menopause 65 77 43 35 26
Post menopause 112 80 41 33 31
ER negative 55 75 40 36 34
ER positive 84 82 54 42 37
PR negative 66 76 41 33 32
PR positive 66 82 56 45 39
Her2 negative 31 94 68 61 58
Her2 positive 14 79 36 36 36
Metastasis 1 31 90 65 55 50
Metastasis 2 68 82 53 43 37
Metastasis 3 18 61 22 17 10
Metastasis 4 20 85 55 50 45
Metastasis 6 38 68 21 13 7
Metastasis 7 3 67 0 0 0
Metastasis 8 7 71 14 14 14
 
 
FACTOR NO OF CASES SURVIVAL PERCENTAGE
1 yr 3 yr 5 yr 10 yr
Treatment modality
0 4 50 25 25 0
2 72 89 58 46 42
3 1 100 100 100 100
5 35 97 80 77 71
6 43 60 5 2 0
7 3 67 33 33 33
8 8 50 13 13 13
9 12 58 8 0 0
10 4 50 0 0 0
11 6 67 50 0 0
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Discussion  
 
The purpose of the study was to evaluate the role of locoregional 
treatment in metastatic breast cancer since this was a retrospective study 
between the year of 2003 – 2008 all medical records of female metastatic 
breast cancer patients excluding brain metastasis were revised and 
analysed with a following factors such as menopausal status, hormone 
receptor status, HER2 neu status, no of metastasis (including visceral 
and non-visceral)   
 
 65 patients in this study were premenopausal and 112 patients 
were belonged to postmenopausal group 55 patients were ER negative 
and 84 patients were ER positive and out of 195 patients 14 patients 
were HER2 positive and 31 patients were HER2 negative  and in the 
remaining cases status not known. 
 
 31 patients had single bone metastasis and 68 pts had multiple 
bone metastasis 18 patients had liver metastasis and 21 patients had lung 
metastasis  2 patients had metastasis liver and lung 3 patients with 
supraclavicular metastasis 7 patients had axillary metastasis.  
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 All patients underwent various treatment modalities according to 
tumour board policy.  74 patients underwent chemo radiation 2 patients 
had chemotherapy followed by surgery 37 patients got concurrent chemo 
radiation followed by surgery. 44 patients received chemotherapy 
alone.3 patients had only radiotherapy 12 patients received 
chemotherapy and harmonic therapy 8 patients had harmonic therapy 
only  in 5 patients radiotherapy and harmonic therapy was given 6 
patients had chemo radiation followed by hormonal therapy. 
 
 Patients survival was analysed at the end of 1 yr, 3 yr, 5 yr, and 10 
years. In patients receiving CT+RT survival at the end of 1 yr was (89%) 
3 yr (58%) 5 yr (46%) 10 yr,(42%). In patients receiving CT+RT + 
surgery at the end of 1 yr was (97%) 3 yr (80%) 5yr(70%) 10 yr,(71%). 
In patients receiving CT only at the end of 1 yr was (60%) 3 yr (5%) 
5yr(2%) 10 yr,(0%). In patients receiving RT only at the end of 1 yr was 
(67%) 3 yr (33%) 5yr(33%) 10 yr,(33%). In patients receiving HT only 
at the end of 1 yr was (50%) 3 yr (13%) 5yr (13%) 10 yr,(13%).  
 
 In patients receiving CT+HT at the end of 1 yr was (58%) 3yr 
(8%) 5yr(0%) 10 yr,(0%). In patients receiving RT + HT at the end of 1 
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yr was (50%) 3yr(0%) 5yr(0%) 10 yr,(0%). In patients receiving CT+RT 
+ HTat the end of 1 yr was (67%) 3yr(50%) 5yr(0%) 10 yr,(0%). 
 
Conclusion 
The data reported in this retrospective study confirmed that 
chemo-radiation improved overall survival and symptomatic local 
control were demonstrated in locoregionally treated patients with 
metastatic breast cancer. The optimal local management of patients with 
metastatic breast cancer remains unknown. An ongoing phase III trial, 
E2108, has been designed to assess the effect of locoregional 
management in metastatic patients responding to first-line systemic 
therapy.Loco regional radiation can be an integral part in metastatic 
breast cancer treatment to improve the quality of life. If the patient did 
not have any metastasis at the end of one year mastectomy can be added 
to still more improve the local control according to this study as there is 
a significant overall survival and better local control with concurrent 
chemo radiation hence RT has a integral part  in the management of 
metastatic breast cancer.   
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